Pressure intensifies on Novartis as bolt-on deal strategy faces major test
Novartis is facing scrutiny towards its merger and acquisition (M&A) strategy after trial setbacks have rocked investors’ confidence in its …
Post
-
-
Scholar Rock’s muscle-targeting SMA therapy Isemblyd lands FDA approval
The US Food and Drug Administration (FDA) approved Scholar Rock’s rare neuromuscular disease therapy, Isemblyd (apitegromab), making it the first …
-
The rare disease revolution: The state of play for CGTs in orphan diseases
Rare diseases are chronic conditions that affect between 3.5% and 5.9% of the global population. About 80% of rare diseases …
-
HIV charities lament NICE snub for Gilead’s twice-yearly lenacapavir
The National Institute for Health and Care Excellence (NICE) has recommended against reimbursement for Gilead’s twice-a-year PrEP medication lenacapavir, prompting …
-
ERS 2026: BMI, type-2 inflammation, and asthma attack risk
On 7 September, at the European Respiratory Society (ERS) 2026 Annual Meeting, a group of investigators, which included both academic …
-
ERS 2026: BMI, type-2 inflammation, and asthma attack risk
On 7 September, at the European Respiratory Society (ERS) 2026 Annual Meeting, a group of investigators, which included both academic …
-
Staunch biotech competition spurs new secretive tactics, shifts investor approach
In recent years, the pharma and biotech landscape has experienced several seismic geopolitical and technological shifts, including China’s rise to …
-
Exegenesis Bio and Modalis sign research deal for Duchenne therapy
Exegenesis Bio and Modalis Therapeutics have entered a research partnership and licence agreement to progress MDL-201, a therapeutic candidate for …
-
ABEC to expand global manufacturing network with new Wilson facility
ABEC is set to open a new manufacturing facility in Wilson, North Carolina, US, expanding its network for biopharmaceutical process …
-
Encoded secures $275m for Dravet syndrome gene therapy
Encoded Therapeutics has raised $275m in a Series F financing round to advance development of its disease-modifying therapy (DMT) for …
-
Podcast: key readouts from ESC and ERS
It's conference season again. In this episode, the healthcare team rounds up the latest readouts and emerging themes from two …
-
Bayer’s Hyrnuo set for the NSCLC frontlines on accelerated FDA label expansion
Bayer has landed an accelerated US approval for its non-small cell lung cancer (NSCLC) therapy, Hyrnuo (sevabertinib), expanding the drug’s …
-
HHS appoints permanent FDA CBER, CDER heads
The US Department of Health and Human Services (HHS) has selected four senior leaders to assume permanent positions in the …
-
Solstice Oncology secures $225m to drive porustobart’s development for cancer
Harbour BioMed’s partner Solstice Oncology has raised $225m in funding to advance its lead candidate, porustobart, a neoadjuvant immuno-oncology therapy. The …
-
TwoStep Therapeutics raises $62.5m in funding to advance TS-104
TwoStep Therapeutics has raised $62.5m in an oversubscribed Series A financing round to support its lead peptide-drug conjugate, TS-104, for …
